Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy
Allergy · 2025-01 · 80 (1) · 215-226
DOI: 10.1111/all.16341 ↗At a glance
Journal article in Allergy, published online on 2024-09-28. Written by Noemi Bachmeier-Zbären and 13 co-authors. Institution: Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland. Major MEDLINE topics: Peanut Hypersensitivity, Mast Cells, Homeodomain Proteins. Cited 18 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Food Allergy and Anaphylaxis Program at the Hospital for Sick Children, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Innosuisse - Schweizerische Agentur für Innovationsförderung.
Abstract (original language)
Background
Peanut allergy is among the most severe and common food allergies. The diagnosis has a significant impact on the quality of life for patients and their families. An effective management approach depends on accurate, safe, and easily implementable diagnostic methods. We previously developed a cell‐based assay using Hoxb8 mast cells (Hoxb8 MCs) aimed at improving clinical allergy diagnosis. In this study, we assessed its diagnostic performance by measuring blinded sera from a prospectively enrolled and pre‐validated peanut allergy cohort.
Methods
Hoxb8 MCs were passively sensitized with sera from peanut‐allergic and peanut tolerant children and adolescents ( n = 112). Degranulation of Hoxb8 MCs was quantified upon stimulation with dose‐titrated peanut extract by means of flow cytometry, using CD107a as activation marker. The results from the Hoxb8 mast cell activation test (Hoxb8 MAT) were compared to established diagnostic assays such as the skin prick test (SPT), specific IgE (sIgE) levels, and the basophil activation test (BAT). Additionally, serum samples from BAT nonresponders were assessed with the Hoxb8 MAT.
Results
Hoxb8 MAT displayed a robust dose‐dependent activation to peanut extract, with a cutoff value of ≤5.2% CD107a positive cells. The diagnostic accuracy was highest at allergen concentrations ≥100 ng/mL, with an area under the receiver operating characteristic curve (AUROC) of 0.97, 93% sensitivity, and 96% specificity, outperforming traditional SPT and sIgE tests. When compared to BAT, Hoxb8 MAT exhibited comparable diagnostic efficacy. Moreover, sera from BAT nonresponders were accurately classified into allergics and nonallergics by the Hoxb8 MAT.
Conclusions
The Hoxb8 MAT demonstrated a very good diagnostic precision in patients prospectively assessed for peanut allergy comparable to the fresh whole blood‐based BAT. Additionally, it demonstrated its value for accurate classification of BAT nonresponders into allergic and nonallergic individuals. Further investigations into its utility in the routine clinical setting are warranted.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland.
- Centre for Computational Medicine, Hospital for Sick Children, Toronto, Ontario, Canada.
- Department for BioMedical Research, Lung Precision Medicine (LPM), University of Bern, Bern, Switzerland.
- Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
- Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Division of Immunology and Allergy, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
ORCID profiles: Jennifer A Hoang, Julia E M Upton, Thomas Kaufmann, Alexander Eggel, Thomas Eiwegger
Funding
- Food Allergy and Anaphylaxis Program at the Hospital for Sick Children
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Innosuisse - Schweizerische Agentur für Innovationsförderung
Cite
APA
Bachmeier-Zbären, N., Celik, A., van Brummelen, R., Roos, N., Steinmann, M., Hoang, J. A., Yin, X., Ditlof, C. M., Duan, L., Upton, J. E. M., Kaufmann, T., Eggel, A., Eiwegger, T., & MONAS working group (2025). Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy. Allergy, 80(1), 215-226. https://doi.org/10.1111/all.16341
Vancouver
Bachmeier-Zbären N, Celik A, van Brummelen R, Roos N, Steinmann M, Hoang JA, et al. Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy. Allergy. 2025;80(1):215-226. doi:10.1111/all.16341
BibTeX
@article{BachmeierZbren2025,
author = {Bachmeier-Zbären, Noemi and Celik, Alper and van Brummelen, Robin and Roos, Nadine and Steinmann, Melanie and Hoang, Jennifer A and Yin, Xiaojun and Ditlof, Christina M and Duan, Lucy and Upton, Julia E M and Kaufmann, Thomas and Eggel, Alexander and Eiwegger, Thomas and MONAS working group, MONAS working group},
title = {Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy},
journal = {Allergy},
year = {2025},
volume = {80},
number = {1},
pages = {215--226},
doi = {10.1111/all.16341}
}
EUVIMED